Nasdaq · Common Stock · In Vitro & In Vivo Diagnostic Substances
25 entities across 19 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-07-30 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| GeneSeek Australia | Australia | |
| GeneSeek Canada Properties I, Inc. | Canada | |
| GeneSeek Canada, Inc. | Canada | |
| GeneSeek UK Ltd | United Kingdom | |
| Megazyme, Ltd. | Ireland | |
| NeoG Corp. | Philippines | |
| Neogen Argentina S.A. | Argentina | |
| Neogen Asia (Thailand) Co, Ltd | Thailand | |
| Neogen Australasia Pty Limited | Australia | |
| Neogen Bio-Scientific Technology (Shanghai) Co., Ltd. | China | |
| Neogen Chile SpA | Chile | |
| Neogen Colombia SAS | Colombia | |
| Neogen do Brasil Productos Para Labratories LTDA. | Brazil | |
| Neogen Food and Animal Security (India) PVT, LTD | India | |
| Neogen Food Safety Brazil, Ltda | Brazil | |
| Neogen Food Safety Canada Corporation | Canada | |
| Neogen Food Safety Switzerland GmbH | Switzerland | |
| Neogen Germany GmbH | Germany | |
| Neogen Ireland Limited | Ireland | |
| Neogen Italia S.r.l. | Italy | |
| Neogen Japan Kabushiki Kaisha | Japan | |
| Neogen Korea Limited | South Korea | |
| Neogen Latinoamerica S.A.P.I. DE C.V. | Mexico | |
| Neogen Poland Sp. Zoo | Poland | |
| Rogama Industria e Comercio Ltda. | Brazil |
Two standard screens, computed from the XBRL in FY2026 against FY2025. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2021 | $468.5M | $60.9M | $54.4M | 45.9% | 107,120,000 |
| FY2022 | $527.2M | $48.3M | $43.6M | 46.1% | 108,020,000 |
| FY2023 | $822.4M | −$22.9M | −$24.7M | 49.4% | 188,881,000 |
| FY2024 | $924.2M | −$9.4M | −$76.2M | 50.2% | 216,481,878 |
| FY2025 | $894.7M | −$1.1B | −$46.4M | 47.1% | 216,894,861 |
| FY2026 | $870.4M | −$7.9M | $31.9M | 46.9% | 217,500,000 |
12 institutions tracked — 5 added, 5 reduced, 2 opened a new position, 1 sold out. Index money added 1,437,329 shares while active managers cut 3,507,262.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | Active fund | 3,145,672 | −1,494,862 | $28.3M |
| CITADEL ADVISORS LLC | Hedge fund | 691,829 | −1,273,975 | $6.2M |
| BlackRock, Inc. | Index | 33,431,015 | +810,010 | $300.5M |
| FMR LLC | Active fund | 1,165,781 | −739,562 | $10.5M |
| STATE STREET CORP | Index | 8,946,377 | +356,033 | $80.4M |
| JPMORGAN CHASE & CO | Active fund | 667,548 | +315,014 | $6.2M |
| MORGAN STANLEY | Active fund | 4,306,091 | −274,336 | $38.7M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 5,832,899 | +271,286 | $52.4M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 500,355 | −89,694 | $4.5M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 301,362 | +50,153 | $2.7M |
RENAISSANCE TECHNOLOGIES LLC, NORGES BANK hold a position with no prior filing to compare against, so their change is unknown rather than zero — and they are left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
NEOGEN CORP files under SIC 2835 — all 4 in vitro & in vivo diagnostic substances companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
